A confirmatory (phase III) study of the efficacy and safety of NS-304 (selexipag) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Selexipag (Primary)
- Indications Hypertension; Thromboembolism
- Focus Therapeutic Use
- Sponsors Nippon Shinyaku
Most Recent Events
- 21 Apr 2022 Status changed from recruiting to completed.
- 10 Dec 2021 New trial record